GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Halberd Corp (OTCPK:HALB) » Definitions » Capex-to-Revenue

Halberd (Halberd) Capex-to-Revenue : 0.00 (As of Jul. 2023)


View and export this data going back to 2009. Start your Free Trial

What is Halberd Capex-to-Revenue?

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue.

Halberd's Capital Expenditure for the six months ended in Jul. 2023 was $0.00 Mil. Its Revenue for the six months ended in Jul. 2023 was $0.00 Mil.

Hence, Halberd's Capex-to-Revenue for the six months ended in Jul. 2023 was 0.00.

Halberd Capex-to-Revenue Historical Data

The historical data trend for Halberd's Capex-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Halberd Capex-to-Revenue Chart

Halberd Annual Data
Trend Jul08 Jul22 Jul23
Capex-to-Revenue
46.29 0.50 -

Halberd Semi-Annual Data
Jul08 Jul22 Jul23
Capex-to-Revenue 46.29 0.50 -

Competitive Comparison of Halberd's Capex-to-Revenue

For the Biotechnology subindustry, Halberd's Capex-to-Revenue, along with its competitors' market caps and Capex-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Halberd's Capex-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Halberd's Capex-to-Revenue distribution charts can be found below:

* The bar in red indicates where Halberd's Capex-to-Revenue falls into.


Halberd Capex-to-Revenue Calculation

Halberd's Capex-to-Revenue for the fiscal year that ended in Jul. 2023 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (0) / 0.003
=0.00

Halberd's Capex-to-Revenue for the quarter that ended in Jul. 2023 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (0) / 0.003
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Halberd  (OTCPK:HALB) Capex-to-Revenue Explanation

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue. The ratio shows how aggressively the company reinvests its revenue back into productive assets. However, a high ratio potentially indicates that the company has invested too much in innovation and infrastructure, taking up funds that could be used to boost productivity and increase revenue. Therefore, a high Capex to Revenue Ratio could be a positive or a negative sign depending on how effectively a company converts those investments into future earnings.

Halberd Capex-to-Revenue Related Terms

Thank you for viewing the detailed overview of Halberd's Capex-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Halberd (Halberd) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Halberd Corp (OTCPK:HALB) » Definitions » Capex-to-Revenue
Comparable Companies
TSSI SWMM SFHI VSR ETOLF ESOA ENG LYOPF BBHDF RCMT LMB CUUHF GV IBIBF LAYN EMFGF LOUIF ORN WLDN GLDD
Traded in Other Exchanges
N/A
Address
P.O. Box 25, Jackson Center, PA, USA, 16133
Website
https://www.halberdcorporation.com
Halberd Corp is a research-based biotechnology company seeking to discover and develop medical treatments for a range of diseases. The Company's extracorporeal treatment is designed to treat hard-to-cure blood-borne, neurologic and infectious diseases. The Company's patented methodology removes the appropriate bodily fluid from the patient, in a continuous fashion, like dialysis, or in a batch process, like blood sample testing.
Executives
John Christopher Maddox director, 10 percent owner, officer: President, COO, Treasurer and, other: Interim CFO 10755 VERNON, HUNTINGTON WOODS MI 48070
Mark Sven Lundquist director, 10 percent owner, officer: CEO, Secretary and Director 24655 TUDOR LANE, FRANKLIN MI 48025
Cocco Nicholas A. Jr. director 50104 N. JIMMY COURT, CHESTERFIELD MI 48047-1898
Leland Michael Thomas director 280 LASALLE PLACE, GROSSE POINTE FARMS MI 88236